BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 34268792)

  • 1. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
    Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
    J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
    Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
    Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
    Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
    Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
    Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
    Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing.
    Dai D; Tan Y; Guo L; Tang A; Zhao Y
    Eur J Endocrinol; 2020 Jan; 182(1):111-121. PubMed ID: 31721725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
    Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
    Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
    Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
    Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
    Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
    Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-146b-3p Promotes Cell Metastasis by Directly Targeting
    Yu C; Zhang L; Luo D; Yan F; Liu J; Shao S; Zhao L; Jin T; Zhao J; Gao L
    Thyroid; 2018 Dec; 28(12):1627-1641. PubMed ID: 30244634
    [No Abstract]   [Full Text] [Related]  

  • 10. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
    Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
    OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma.
    Chen W; Li G; Li Z; Zhu J; Wei T; Lei J
    Endocrine; 2022 Mar; 75(3):846-855. PubMed ID: 34854020
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Duan Y; Zhang Y; Peng W; Jiang P; Deng Z; Wu C
    Pharmazie; 2020 Jun; 75(6):266-270. PubMed ID: 32539923
    [No Abstract]   [Full Text] [Related]  

  • 13. MiR-141-3p Suppresses Tumor Growth and Metastasis in Papillary Thyroid Cancer via Targeting Yin Yang 1.
    Fang M; Huang W; Wu X; Gao Y; Ou J; Zhang X; Li Y
    Anat Rec (Hoboken); 2019 Feb; 302(2):258-268. PubMed ID: 30290400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
    Li M; Song Q; Li H; Lou Y; Wang L
    PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B.
    Lu H; Zhu C; Ruan Y; Fan L; Ruan Z; Chen Q; Yuan J; Xu Y; Wang H; Wei Q
    Biomed Res Int; 2022; 2022():7488708. PubMed ID: 35342753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
    Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
    World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
    He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
    BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.
    Zou X; Gao F; Wang ZY; Zhang H; Liu QX; Jiang L; Zhou X; Zhu W
    Chin Med J (Engl); 2020 Nov; 133(21):2543-2551. PubMed ID: 33009019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
    Liu ZM; Wu ZY; Li WH; Wang LQ; Wan JN; Zhong Y
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3421-3430. PubMed ID: 31081096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.